11 Best Most Active Stocks To Buy According to Analysts

5. Novo Nordisk (NYSE:NVO)

Number of Hedge Fund Holders: 60

Average Volume (3-Month): 000

Average Upside Potential as of June 20: 34.75%

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development. The decision is based on promising results from two early-phase clinical trials: one for a once-weekly subcutaneous formulation and another for a once-daily oral formulation. These were published in The Lancet.

Both formulations will progress to Phase 3 for weight management, which is a move supported by completed clinical studies and positive feedback from regulatory authorities. The executive vice president for Development at Novo Nordisk, Martin Holst Lange, expressed satisfaction with the results and regulatory feedback and highlighted the company’s commitment to addressing obesity and expanding treatment options.

Amycretin is a unimolecular, long-acting GLP-1 and amylin receptor agonist, which is designed to target appetite regulation. It is being developed for adults with overweight or obesity, and also as a potential treatment for adults with type 2 diabetes. While Amycretin is not yet approved in the US for weight loss, these positive early-phase results strongly support its continued investigation in larger and longer-term Phase 3 trials to further assess its efficacy and safety.

Novo Nordisk (NYSE:NVO) engages in the research & development, manufacture, and distribution of pharmaceutical products internationally. It has 2 segments: Diabetes & Obesity Care and Rare Disease.